As of Wednesday close, United Therapeutics Corporation’s (NASDAQ:UTHR) stock was down -$4.07, moving down -1.50 percent to $266.86. The average number of shares traded per day over the past five days has been 284,700 shares. 5 times new highs have been achieved over the past 5 days, with a $5.81 gain in that time frame. In the last twenty days, the average volume was 441,550, while in the previous 50 days, it was 368,918.
Since last month, UTHR stock rose 17.68%. Shares of the company fell to $218.82 on 10/24/22, the lowest level in the past month. A 52-week high of $271.22 was reached on 11/23/22 after having rallying from a 52-week low of $158.38. Since the beginning of this year, UTHR’s stock price has risen by 23.50% or $50.78, and marked a new high 16 times. However, the stock has declined by -1.61% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
UTHR stock investors should be aware that United Therapeutics Corporation (UTHR) stock had its last reported insider trading activity 3 days ago on Nov 21. ROTHBLATT MARTINE A, the CHAIRPERSON & CEO of the company, disposed of 8,000 shares for $266.93 on Nov 21. It resulted in a $2,135,472 divestment by the insider. ROTHBLATT MARTINE A sold 8,000 shares at an average price of $263.97 on Nov 18. The insider now owns 130 shares following the transaction. On Nov 17, CHAIRPERSON & CEO ROTHBLATT MARTINE A sold 8,000 shares at $261.17 apiece. The transaction was valued at $2,089,392.
Right now, United Therapeutics Corporation (UTHR) has a P/E ratio of about 18.16. The stock’s beta is 0.59. Besides these, the trailing price-to-sales (P/S) ratio of 6.54, the price-to-book (PB) ratio of 2.66, and the price-to-cash flow ratio of 17.92 may also be considered.
In the three months ended September 29, United Therapeutics Corporation’s quick ratio stood at 9.40, while its current ratio was 9.70, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.18, and the total debt-to-equity ratio was 0.18. On the profitability front, the trailing twelve-month gross margin is 93.20% percent. In the year ended September 29, operating margins totaled 52.30%. Based on annual data, UTHR earned $1.56 billion in gross profit and brought in $1.69 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 9.20%. Return on equity (ROE) for the past 12 months was 16.60%.
In United Therapeutics Corporation’s quarter-end financial report for September 29, it reported total debt of $800.0 million against cash and short-term investments of $1.65 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. UTHR’s revenue rose 13.82% to $466.9 million during the quarter, while net income inched up to $516.0 million. While analysts expected United Therapeutics Corporation to report $3.89 quarterly earnings, the actual figure was $4.91 per share, beating the consensus estimate by 26.20%. During the quarter, the company generated $327.2 million in EBITDA. The liabilities of United Therapeutics Corporation were 1.22 billion at the end of its most recent quarter ended September 29, and its total debt was $800.0 million. The value of shareholders’ equity is $45.58 million.
This quick technical analysis looks at United Therapeutics Corporation’s (UTHR) price momentum. With a historical volatility rate of 24.35%, the RSI 9-day stood at 66.56% on 23 November.
With respect to its five-day moving average, the current United Therapeutics Corporation price is up by +2.23% percent or $5.81. At present, UTHR shares trade +17.20% above its 20-day simple moving average and +12.53% percent above its 100-day simple moving average. However, the stock is currently trading approximately +21.75% above its SMA50 and +33.67% above its SMA200.
Stochastic coefficient K was 86.76% and Stochastic coefficient D was 87.84%, while ATR was 7.88. Given the Stochastic reading of 75.17% for the 14-day period, the RSI (14) reading has been calculated as 67.78%. As of today, the MACD Oscillator reading stands at 5.24, while the 14-day reading stands at 4.57.
Morgan Stanley launched its rating on United Therapeutics Corporation (NASDAQ: UTHR) to an Overweight in a note to investors on October 11, 2022. United Therapeutics Corporation (UTHR) has been rated Overweight by analysts. According to 0 brokerage firms, UTHR is a sell, and 1 firms recommend it is a Hold. There are 2 analysts who say the stock is underweight. A total of 0 analysts rate United Therapeutics Corporation stock as buy, with 10 recommending it as overweight.
With a median target price of $295.00, the current consensus forecast for the stock is $150.00 – $375.00. Based on these forecasts, analysts predict United Therapeutics Corporation (UTHR) will achieve an average price target of $284.30.